This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Remaining (Pharmaco)Vigilant Post-Brexit
Pharmacovigilance has become increasingly integrated across the EU, but the Article 50 clock is ticking. A Brexit deal that fails to deliver continued close cooperation between the UK and the EU is not an option for patients.
